Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LGRO vs ABOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABOS Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 5–3 Matrix Metrics)

ABOS Overall Winner 6-Pillar Tally: LGRO 0 – 4 ABOS (2 Tie) Matrix Metrics: LGRO 3 – 5 ABOS

As of Nov 16, 2026, Acumen Pharmaceuticals, Inc. (ABOS) is the stronger overall head-to-head candidate over Level Four Large Cap Growth Active ETF (LGRO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LGRO carries a Unified Composite Score of 63.4/100 (BUY) at $45.00 (N/M Forward P/E, N/A operating margin), whereas ABOS carries 57.4/100 (HOLD) at $0.22 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While LGRO currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. ABOS 57.4/100 HOLD), ABOS captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: LGRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LGRO vs ABOS
LGRO NASDAQ
Level Four Large Cap Growth Active ETF
Institutional Equity
$45.00
-2.05% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.04β · 24% Vol
Unified Composite Score
63.4 / 100 BUY
Tech 74.0 Fund 65.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.8%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $46.33 · SMA50: $46.73
ABOS NASDAQ Head-to-Head Winner
Acumen Pharmaceuticals, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.22
+0.93% 1D
Market Cap $15.5M
TTM Revenue $329,000
Forward P/E N/M
Beta / 30D Vol 2.60β · 335% Vol
Unified Composite Score
57.4 / 100 HOLD
Tech 76.0 Fund 62.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.7%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.00 · SMA50: $1.79

6-Pillar Scorecard Institutional Category Breakdown (LGRO 0 – 4 ABOS)

Columns: Metric · LGRO · ABOS
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABOS
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $329,000
Market Cap N/A $15.5M
3. Profitability & Quality ABOS
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -162.7%
4. Balance Sheet & Cash Flow ABOS
Cash Generation (TTM) N/A -$105M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $27M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABOS
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 232.4% (41st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LGRO (3) vs ABOS (5)
Institutional Metric LGRO ABOS Criterion Row Edge
Market Capitalization
Scale
N/A $15.5M Larger Scale ABOS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth ABOS
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin ABOS
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ABOS
Return on Equity (ROE)
Capital Efficiency
N/A -162.7% Higher ROE ABOS
52-Week Range Position
Momentum
74% ($36–$48) 1% ($0–$4) Stronger Trend LGRO
Beta / 30D Volatility
Risk Regime
1.04β · 24% Vol 2.60β · 335% Vol Lower Realized Risk LGRO
Unified Institutional Score
Composite Signal
63.4 / 100 (BUY) 57.4 / 100 (HOLD) Higher Composite LGRO
Trailing 12M Revenue (USD)
Operating Scale
N/A $329,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$105M EBITDA ($27M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LGRO +83.6 pp
LGRO: -3.62% · ABOS: -87.22%
3M Horizon LGRO +87.98 pp
LGRO: -4.14% · ABOS: -92.12%
6M Horizon LGRO +96.67 pp
LGRO: +6.58% · ABOS: -90.09%
1Y Horizon LGRO +99.54 pp
LGRO: +11.47% · ABOS: -88.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LGRO vs ABOS. Trailing 12-month operating profitability (LGRO N/A vs ABOS 0.0%) and valuation multiples (LGRO N/M vs ABOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LGRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$329,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-162.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LGRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LGRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABOS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 232.4%
IV Percentile 41st %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LGRO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABOS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LGRO vs ABOS Key Questions & Quantitative Answers

As of Nov 16, 2026, Acumen Pharmaceuticals, Inc. (ABOS) is the stronger overall head-to-head candidate over Level Four Large Cap Growth Active ETF (LGRO) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LGRO carries a Unified Composite Score of 63.4/100 (BUY) at $45.00 (N/M Forward P/E, N/A operating margin), whereas ABOS carries 57.4/100 (HOLD) at $0.22 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While LGRO currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. ABOS 57.4/100 HOLD), ABOS captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: LGRO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4); meanwhile ABOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABOS leads the Growth & Scale pillar: LGRO posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABOS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $329,000 TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LGRO generates N/A in USD-normalized revenue versus $329,000 for ABOS. In operating R&D and SG&A reinvestment, LGRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABOS.

LGRO and ABOS trade at balanced relative valuation multiples. LGRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LGRO (N/A ROE) versus ABOS (-162.7% ROE) capital efficiency.

In options market volatility and institutional positioning, LGRO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 24% Vol realized risk). By comparison, ABOS carries 232.4% implied volatility (41st %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.60β · 335% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.